Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Harvey is active.

Publication


Featured researches published by Michael Harvey.


Internal Medicine Journal | 2002

Hickman catheter complications in a haematology unit, 1996–98

R. Soo; Iain B. Gosbell; J. H. Gallo; Michael Harvey; Lindsay Dunlop; P. Motum; D. Rosenfeld

Ninety-nine dual-lumen Hickman catheters were inserted in 77 patients (46 male and 31 female). A review of 96 catheters (44 male and 30 female patients) was conducted (Table 1).The most common diagnoses were: (i) acute myeloid leukaemia (in 33 patients), (ii) acute lymphoblastic leukaemia (in 18 patients) and (iii) non-Hodgkin’s lymphoma (in 18 patients). A further eight patients had other diagnoses. The preoperative full blood count showed: (i) a mean haemoglobin level of 112 g/L (median 110 g/L; range 77–153 g/L), (ii) a mean neutrophil count of 4.5 × 109/L (median 2.2 × 109/L; range 0–46 × 109/L), and (iii) a mean platelet count of 150 × 109/L (median 96 × 109/L; range 3–912 × 109/L).


Respirology case reports | 2015

Endobronchial deposits of chronic lymphocytic leukemia - an unusual cause of central airway obstruction.

Miranda Maw; Michael Harvey; Zinta Harrington; Melissa Baraket; Renn Montgomery; Jonathan P. Williamson

A 66‐year‐old woman with a background of chronic lymphocytic leukemia (CLL) was admitted to the hospital on several occasions with recurrent episodes of community‐acquired pneumonia. Computed tomography and bronchoscopy revealed multiple obstructing endobronchial polyps. Post‐obstructive pneumonia together with immunoglobulin G deficiency was considered the most likely cause of these recurrent infections. Bronchoscopy was performed for removal of the critically obstructing lesions. Histopathology revealed replacement of bronchial mucosa with CLL deposits. Despite a brief window of infection‐free survival following therapy, she remained susceptible to pneumonia with further hospital admissions and eventually died from her disease.


Transgenic Research | 1993

Human Gγ and Aγ globin gene constructs containing the 3′ Aγ enhancer show persistent fetal expression in transgenic mice

Michael Harvey; J. Crosbie; Ronald J. Trent

Transgenic mice were produced from two 13 kb constructs containing the fetal (γ) globin genes. Each construct consisted of a Gγ globin gene linked to one of two alternative Aγ genes. The first construct contained a normal Gγ gene plus and Aγ gene with the −198T→C hereditary persistence of fetal haemoglobin (HPFH) mutation. In the second, a normal Gγ gene was linked to a Aγ gene with a−222 to −225 four base pair deletion in the promoter. This latter mutation has been associated with low Aγ expression in humans. Both Aγ genes in these constructs also contained the 3′ flanking enhancer. The two different constructs showed expression throughout gestation from day 11 yolk sac, through the fetal period and for a variable time during the first three postnatal weeks. Thereafter, no expression of any of the γ-globin genes was seen in adult erythroid tissues. Transcription from the normal Gγ and HPFH Aγ genes in the first construct paralleled each other in developmental timing, with a proportionate excess of Aγ more evident in later gestation. Gγ and Aγ mRNA transcripts from the normal Gγ+4 bp deletional Aγ construct were unable to be distinguished because of a 3′ Gγ-like conversion in the deletional Aγ gene. Combined γ-globin expression from the two genes in this second construct was detectable until just after birth, as seen with the individual genes in the first construct. Previous work has shown that when individual Gγ and Aγ transgenes are introduced into mice unlinked, without the locus control region (LCR), embryonic expression only is seen. In the present study, γ-globin expression was evident from both constructs throughout the fetal period of erythropoiesis. This suggests that the additional DNA sequences flanking the γ-globin genes included in these larger constructs are capable of supporting fetal recruitment of the γ-globin genes, independently of the LCR.


Blood Coagulation & Fibrinolysis | 2003

Recombinant activated factor VII for the treatment of life-threatening haemorrhage.

John W Eikelboom; Robert Bird; David Blythe; Luke Coyle; Eng Gan; Michael Harvey; James Isbister; Michael Leahy; David McIlroy; Farhad Rahimpanah; Sundra Ramanthan; Simone Strasser; Christopher Ward; Andrew Watts; Simon Towler; Qilong Yi


The Medical Journal of Australia | 1995

Massive blood transfusion in a tertiary referral hospital. Clinical outcomes and haemostatic complications.

Michael Harvey; Greenfield Tp; Sugrue Me; David Rosenfeld


American Journal of Hematology | 1994

Recombinant interferon alpha and hemolytic uremic syndrome: Cause or coincidence?

Michael Harvey; David Rosenfeld; David J. Davies; Bruce M. Hall


Emergency Medicine Australasia | 2003

Implications for urgent transfusion of uncrossmatched blood in the emergency department: The prevalence of clinically significant red cell antibodies within different patient groups

Josobel Saverimuttu; Tony Greenfield; Irene Rotenko; John A. Crozier; Bin Jalaludin; Michael Harvey


Australian and New Zealand Journal of Medicine | 1986

Complications associated with indwelling venous Hickman catheters in patients with hematological disorders.

Michael Harvey; Ronald J. Trent; D. Joshua; G. Ramsey-Stewart; D. W. Storey; Henry M. Kronenberg


Clinical and Laboratory Haematology | 2006

The immature reticulocyte fraction : a negative predictor of the harvesting of CD34 cells for autologous peripheral blood stem cell transplantation

Lindsay Dunlop; J. Cohen; Michael Harvey; J. H. Gallo; P. Motum; D. Rosenfeld


Australian and New Zealand Journal of Medicine | 1995

Autologous blood stem cell transplantation for haematological malignancy: treatment-related mortality of 2%

Kerry Atkinson; Anthony J. Dodds; Sam Milliken; A. Concannon; Keith Fay; Mark Harris; S. Flecknoe-Brown; D. Lind; R. McKinley; J. Rutovitz; David Rosenfeld; Michael Harvey; K. Downs; D. Flattery; J. Song; A. Green; V. Quigley; T. Hawkins

Collaboration


Dive into the Michael Harvey's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

D. Rosenfeld

University of New South Wales

View shared research outputs
Top Co-Authors

Avatar

J. H. Gallo

University of New South Wales

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

P. Motum

University of New South Wales

View shared research outputs
Top Co-Authors

Avatar

Ronald J. Trent

Royal Prince Alfred Hospital

View shared research outputs
Top Co-Authors

Avatar

Bin Jalaludin

University of New South Wales

View shared research outputs
Top Co-Authors

Avatar

Bruce M. Hall

University of New South Wales

View shared research outputs
Top Co-Authors

Avatar

D. Flattery

Sydney Adventist Hospital

View shared research outputs
Top Co-Authors

Avatar

D. Joshua

Royal Prince Alfred Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge